PinCell
4.5.2023 10:01:39 CEST | ACCESS Newswire | Press release
Proprietary transgenic mouse produces human form of FasL protein
MILAN, ITALY / ACCESSWIRE / May 4, 2023 / PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent in-vivo studies of its lead candidate (PC111) using a proprietary transgenic mouse model expressing the human form of the target protein (FasL). PinCell is a spin-off of the University of Modena and Reggio Emilia and was seed financed by Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.PinCell's monoclonal antibody, PC111, proved effective in the neonatal passive pemphigus mouse model, considered the gold standard for testing treatments of pemphigus, a rare and debilitating skin disease marked by extreme blistering of skin and mucosae. Using the proprietary transgenic mouse, PC111 inhibited the production of blisters by at least 80%, confirming previous studies in in-vitro and ex-vivo human models of pemphigus. PC111 was also shown to dose-dependently neutralize human FasL in another in-vivo setting involving the Concanavalin-A liver model, which induces an acute release of FasL into the blood.
"This is a great achievement for the company," said Dr. Antonino (Tony) Amato, Chief Executive Officer of PinCell. "It provides for the first time in-vivo proof of concept evidence of PC111 effect in a humanized disease setting."
"We feel a real sense of accomplishment," said Prof. Carlo Pincelli, founder and Chief Medical Officer at PinCell. "By developing a proprietary model, we have now shown that our antibody does indeed inhibit blister formation by binding specifically to the human target."
"What is more, the humanized FasL mouse model could prove to be a valuable tool to study the involvement of the Fas/FasL pathway in other diseases in which this pathway may play a key role in disease development and progression," Prof. Pincelli added.
About pemphigus
Pemphigus is a rare condition that affects about 300,000 patients worldwide. Conservatively, a treatment based on PC111 would be beneficial for over 30 percent of this population who are relapsing or refractory to first line treatments.
PinCell's therapy will be an alternative to steroids or immunosuppressants currently prescribed or under development. By acting downstream from the immune system, at the level of skin cells, PC111's innovative mode of action will contribute to the reduction or the avoidance of steroids/immunosuppressants, while showing a rapid onset of action.
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly undertreated skin diseases. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Prof. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: sofinnovapartners.com
CONTACT: Tony Amato, MD - CEO, PinCell - a.amato@pincell.com - +39-334-6263471
SOURCE: PinCell
View source version on accesswire.com:
https://www.accesswire.com/752528/PinCell-Announces-2-Successful-In-Vivo-Studies-for-Breakthrough-Skin-Disease-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Crestone Air Partners, an Air T Business, Completes Acquisition of Arena Aviation Capital, Surpassing $3.6 Billion in Assets Under Management16.6.2026 23:10:00 CEST | Press release
Milestone reflects Air T's permanent-capital, buy-to-build model and the momentum of its networked aviation portfolio MINNEAPOLIS, MN / ACCESS Newswire / June 16, 2026 / Air T, Inc. (NASDAQ:AIRT) today announced that its majority owned business Crestone Air Partners, a global aviation asset management platform, has completed its acquisition of Arena Aviation Capital - a well-established aviation asset manager with a diversified portfolio and deep airline relationships. The transaction, first disclosed on March 8, 2026, has now closed following the satisfaction of all customary closing conditions and required approvals. The acquisition materially expands Crestone. Assets under management (AUM) as of December 31, 2025, were $800 million; as of March 31, 2026, AUM had grown to $1.2 billion; and post-transaction, the combined platform now comprises $3.6 billion of AUM. Crestone receives standard aviation industry management fees, including origination fees, administrative fees, disposition
On Sale Now! LiberNovo Maxis Big & Tall Ergonomic Chair Debuts, Unlocking a New Level of "Stability, Width, and Comfort" for Prolonged Sitting16.6.2026 18:00:00 CEST | Press release
The Maxis series is live today across the US, Canada, and Europe, starting at €829, with launch savings up to 48% off MSRP. HONG KONG, HK / ACCESS Newswire / June 16, 2026 / LiberNovo's Maxis series goes on sale today, the brand's first line built from the ground up for Big & Tall users rather than scaled up from a standard chair. It ships in three configurations, alongside two additions to the LiberNovo Omni family. Built for the body, not scaled up to fit Maxis targets the three things that fail a larger body in a standard seat: thighs left unsupported, a recline that sways under weight, and support that gives out by mid-afternoon. The 52 cm seat extends fully under the thigh. Multi-density foam holds its shape instead of bottoming out under load. A tall backrest and adjustable neck support hold the spine and neck, with the neck support sitting at the neck rather than behind the head. The frame is BIFMA-certified to 181 kg (399 lb) on a die-cast aluminum alloy base. Recline that hold
MicroVision Brought Onboard by Lake Fusion Technologies and Timberline Aerospace to Accelerate IRIS Sensor Package Deployment16.6.2026 15:20:00 CEST | Press release
Collaboration supports global deployment of advanced situational awareness solutions across commercial, critical infrastructure, security, and government applications REDMOND, WA / ACCESS Newswire / June 16, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, automotive, security and defense applications, today announced recent shipments of its IRIS lidar sensors to Lake Fusion Technologies (LFT) LLC, as LFT and Timberline Aerospace welcome MicroVision onboard to further expand their collaboration and accelerate the deployment of advanced situational awareness solutions. MicroVision recently shipped IRIS sensors to LFT, marking an important milestone as LFT, together with Timberline Aerospace, brings MicroVision more fully into its ecosystem to broaden capabilities and expedite the development and delivery of integrated IRIS Sensor Packages. The deployment will support LFT's continued development and validation activities as it advances sol
Karbon-X Advances Large-Scale Senegal Blue Carbon Project as Second Globally Registered Under Verra's VM0033 Methodology16.6.2026 15:15:00 CEST | Press release
7,500-hectare Senegal blue carbon initiative achieves Verra registration, marking a significant project development milestone for Karbon-X CALGARY, AB / ACCESS Newswire / June 16, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced that its Senegal Blue Carbon Mangrove Project has achieved registration under Verra's Verified Carbon Standard (VCS) and Climate, Community & Biodiversity (CCB) Standards, becoming the second project globally to achieve registration under Verra's VM0033 methodology for tidal wetland and seagrass restoration. Located within Senegal's Sine Saloum Delta and Casamance Estuary regions, the approximately 7,500-hectare project is focused on restoring degraded mangrove ecosystems through reforestation and ecosystem recovery activities. Mangrove forests are among the world's most carbon-rich natural environments, capable o
Leggett Dynamics Launches Smart Brushless Motor & Advances Quiet, Software-Defined Comfort & Motion16.6.2026 13:00:00 CEST | Press release
Reduces Complexity & Cost, Improves Performance, Supports Next-Gen Architectures DETROIT, MI / ACCESS Newswire / June 16, 2026 / Leggett Dynamics today launched its Smart Brushless Motor, a next-generation motion system that simplifies design and vehicle integration, improves NVH and durability and supports evolving software architectures across seating and other motion-control applications. Less Complexity, More Capability Unlike conventional systems, Leggett Dynamics' Smart Brushless Motor can operate with or without a seat-level electronic control unit (ECU), enabling direct communication from the vehicle-level ECU to individual actuators. This streamlined approach supports the industry shift toward more centralized or zonal architectures and enables simplified, scalable integration across multiple seat configurations and trim levels with varying actuator counts. In addition, the motor's design reduces packaging size, weight, and wiring complexity while enhancing sound, durability,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom